Can carboplatin be omitted from neoadjuvant therapy for selected patients with HER2-positive early breast cancer?

The covered comparison found THP noninferior to TCbHP for pathologic complete response, supporting consideration of carboplatin-sparing treatment in selected patients. These findings do not establish that carboplatin should be omitted universally or that long-term outcomes are equivalent.

How useful is circulating tumor DNA in early breast cancer?

Circulating tumor DNA has strong prognostic potential for identifying molecular residual disease and risk of recurrence in early breast cancer. Its clinical actionability remains uncertain because evidence has not yet established that changing treatment based on ctDNA results improves outcomes.

Why is biopsy important when metastatic breast cancer is suspected?

Biopsy helps confirm metastatic disease and better characterize the current illness rather than relying only on imaging or the original tumor profile. The resulting tissue assessment can inform how the recurrence is classified and how subsequent management is considered.

What does the evidence show about Medicaid expansion and breast cancer outcomes?

Recent analyses link Medicaid expansion with improved breast cancer outcomes and fewer deaths. The evidence supports the clinical importance of insurance access across detection and treatment, although the covered material does not provide patient-level effect estimates or define outcomes for every subgroup.

Living with Breast Cancer

Stories from people navigating Breast Cancer — diagnosis, treatment, caregiving, and the ordinary days in between.

23 stories

A breast cancer molecular testing report beside labeled pathology slides and an oncology treatment plan.

Women's Health

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

The FDA indication ties imlunestrant plus abemaciclib to an ESR1-positive result after endocrine therapy progression in ER-positive, HER2-negative advanced breast cancer.

Rayan Salih · November 5, 2026 · 6 min

Blood sample and breast cancer pathology materials prepared for ESR1 biomarker testing

Women's Health

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

The FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine progression. ESR1 testing now determines eligibility.

Dr. Abu Bakar · 6 min read

Blood tubes beside a breast cancer pathology report prepared for ESR1 mutation testing.

Women's Health

Imlunestrant Combo Makes ESR1 Testing a Selection Step

The FDA approval applies to adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation after endocrine-therapy progression. Guardant360 CDx is the companion diagnostic.

Rayan Salih · 7 min read

Breast cancer pathology slides beside a molecular testing report and treatment planning notes.

Women's Health

Imlunestrant Makes ESR1 Testing Actionable in Breast Cancer

The FDA-approved imlunestrant–abemaciclib combination applies to adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine progression.

Rayan Salih · 7 min read

Blood collection tubes beside a breast cancer treatment plan and molecular testing request form.

Women's Health

Camizestrant Links ESR1 Detection to Breast Cancer Care

FDA approval makes an emerging ESR1 mutation actionable during aromatase-inhibitor plus CDK4/6-inhibitor therapy for eligible patients with advanced breast cancer.

Rayan Salih · 6 min read

Breast cancer pathology slides beside a molecular testing report labeled ESR1

Oncology

ESR1-Mutated Breast Cancer Gains Imlunestrant Combination

The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.

Rayan Salih · 6 min read

A blood specimen for ESR1 testing beside a breast cancer pathology report and unbranded medication containers.

Women's Health

Imlunestrant Combination Approved for ESR1 Breast Cancer

The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that progressed after endocrine therapy.

Rayan Salih · 6 min read

A breast cancer pathology slide beside a molecular test report highlighting an ESR1 alteration.

Oncology

FDA Approval of Vepdegestrant: A New ESR1-Targeted Option for Advanced Breast Cancer

FDA approval makes vepdegestrant an option for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy.

Dr. Abu Bakar · 6 min read

Breast cancer pathology slide beside a molecular test report indicating PIK3CA wild-type status.

Oncology

Gedatolisib Approved for PIK3CA-Wild-Type Breast Cancer

The FDA approved gedatolisib plus fulvestrant, with or without palbociclib, after endocrine therapy progression in PIK3CA-wild-type HR-positive, HER2-negative advanced breast cancer.

Rayan Salih · 6 min read

Breast cancer pathology slides beside medication packaging and a clinician’s treatment-planning notes.

Oncology

Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer

A meta-analysis found invasive disease-free survival gains with adjuvant abemaciclib and ribociclib, but not palbociclib, in HR-positive, HER2-negative early breast cancer.

Rayan Salih · 7 min read

Oncology

GLP-1 Receptor Agonists and Breast Cancer Risk Reduction

The metabolic landscape of oncology is rapidly evolving, driven by an expanding understanding of how systemic metabolic dysfunction

Rayan Salih · 8 min read

Oncology

Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions

For decades, the oncology landscape has viewed lifestyle modification as a pleasant, well-intentioned afterthought—a supportive measure for general

Rayan Salih · 10 min read

Pink ribbon and lab equipment symbolize breast cancer awareness and research.

Oncology

ctDNA in Early Breast Cancer: Prognostic Power vs Clinical Actionability

Circulating tumor DNA (ctDNA) is a blood-based signal that is drawing a lot of attention in early breast

Dr. Abu Bakar · 6 min read

doctor, patient, gynecologist, women, females, healthcare and medicine, hospital, medical clinic, medicine, nurse, female doctor

Oncology

Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact

For patients with neoadjuvant HER2+ breast cancer, clinicians are increasingly reconsidering whether carboplatin a platinum chemotherapy drug sometimes

Dr. Abu Bakar · 7 min read

Medical staff attending to a patient with an IV drip in a clinical setting.

Oncology

T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing

Trastuzumab Deruxtecan (T-DXd) is now increasingly emerging as the preferred choice for HER2-low metastatic breast cancer patients, and

Dr. Abu Bakar · 9 min read

State-of-the-art radiation therapy machine used for cancer treatment in a medical facility.

Oncology

Ultra‑Hypofractionated Radiation Therapy for Locally Advanced Breast Cancer

Shorter, higher‑dose radiation therapy schedules are being explored for people with locally advanced breast cancer, and early experience

Dr. Abu Bakar · 6 min read

Women's Health

IOA-244(p110δ PI3K) Stops Breast Tumor Progression Mono/Combo Tx

The experimental compound IOA-244 is targeted to the p110δ isoform of phosphoinositide 3‑kinase (PI3K) and is active in

Rayan Salih · 2 min read

Oncology

THP Noninferior To TCbHP For pCR In HER2+ Early Breast Cancer

The comparison of management of HER2-positive early breast cancer suggests that the addition of carboplatin to any backbone

Rayan Salih · 3 min read

a gloved hand holding a test tube filled with liquid

Oncology

FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC

On March 9, 2026, researchers of early stage HER2-positive breast cancer learned more recent information on the development

Rayan Salih · 3 min read

Woman holds pink ribbon for breast cancer awareness

Oncology

Why Breast Cancer Is Increasing In Younger Women, Explained

The growing numbers of young women with breast cancer, means that prevention and screening programs, as well as

Dr. Abu Bakar · 16 min read

Oncology

Medically-Induced Menopause: Implications for Breast Cancer

Treatment-induced menopause (TIM) is an under-recognized health outcome for women with breast cancer.

Dr. Abu Bakar · 11 min read

white concrete building under blue sky during daytime

Oncology

Medicaid Expansion Prevents Thousands Of Breast Cancer Deaths

Recent analyses and policy conversations point to a clear link between Medicaid expansion and improved outcomes for people

Rayan Salih · 8 min read

Oncology

Importance of Biopsy in Suspected Metastatic Breast Cancer

Why It Matters In order to best understand this patient’s illness, a biopsy is important.

Dr. Abu Bakar · 10 min read

Questions clinicians ask

Can carboplatin be omitted from neoadjuvant therapy for selected patients with HER2-positive early breast cancer?: The covered comparison found THP noninferior to TCbHP for pathologic complete response, supporting consideration of carboplatin-sparing treatment in selected patients. These findings do not establish that carboplatin should be omitted universally or that long-term outcomes are equivalent.
How useful is circulating tumor DNA in early breast cancer?: Circulating tumor DNA has strong prognostic potential for identifying molecular residual disease and risk of recurrence in early breast cancer. Its clinical actionability remains uncertain because evidence has not yet established that changing treatment based on ctDNA results improves outcomes.
Why is biopsy important when metastatic breast cancer is suspected?: Biopsy helps confirm metastatic disease and better characterize the current illness rather than relying only on imaging or the original tumor profile. The resulting tissue assessment can inform how the recurrence is classified and how subsequent management is considered.
What does the evidence show about Medicaid expansion and breast cancer outcomes?: Recent analyses link Medicaid expansion with improved breast cancer outcomes and fewer deaths. The evidence supports the clinical importance of insurance access across detection and treatment, although the covered material does not provide patient-level effect estimates or define outcomes for every subgroup.

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.